Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials

G. Ferguson (Farmington Hills, United States of America), T. Siler (St. Charles, United States of America), D. Lombardi (South San Francisco, United States of America), G. Crater (South San Francisco, United States of America)

Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Session: COPD : inhaled corticosteroids, bronchodilators and eosinophils
Session type: E-poster session
Number: 3244
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America), T. Siler (St. Charles, United States of America), D. Lombardi (South San Francisco, United States of America), G. Crater (South San Francisco, United States of America). Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials. 3244

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: